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Abstract 
Background: The aim of our study was to assess the efficacy of Cerebrolysin administration in Broca’s aphasics with 
acute ischemic stroke. 
  Methods: We registered 2,212 consecutive Broca’s aphasics following an acute ischemic stroke admitted in four 
departments of neurology in Romania, between September 2005 and September 2009. Language was evaluated with the Romanian 
version of the Western Aphasia Battery (WAB). 
The following inclusion criteria were used for this study: age 20-75 years, admission in the hospital within 12 hours from the onset of 
the symptoms, diagnosis of first acute left middle cerebral artery (MCA) ischemic stroke, presence of large artery disease (LAD) 
stroke, a NIHSS score of 5-22 points, and a therapeutic time window within 72 h. Fifty two patients were treated with Cerebrolysin 
(Cerebrolysin group) as an adjunctive treatment. A placebo group, which received saline infusions (n=104 patients) were matched to 
the NIHSS and WAB scores, gender and age of the Cerebrolysin group at baseline. We assessed spontaneous speech (SS), 
comprehension (C), repetition (R), naming (N), and Aphasia Quotient (AQ) scores of the two groups in an open label design, over 90 
days, the mRS scores and mortality.  
Results:  The Cerebrolysin and the placebo groups had similar age (66+/-8 versus 65+/-8 years) and sex ratio (14/38 versus 30/74). 
The mean AQ scores and the mean subscores for 3 subtests of WAB (SS, R, N) were similar at baseline and improved in the 
Cerebrolysin group significantly (p<0.05) over placebo group at all study time points. The mRS score at 90 days was also lower in 
the Cerebrolysin group than in the placebo group. Cerebrolysin and placebo were both tolerated and safe, and no difference in the 
mortality rate was seen (3.8% in each group). 
  Conclusion: Cerebrolysin is effective for the treatment of Broca’s aphasics with a first acute ischemic stroke of the left 
MCA territory. 
Background and purpose 
The aim of the treatment in acute ischemic 
stroke is to limit the damage and to improve recovery by 
reperfusion and neuroprotection. Thrombolysis is 
restricted to a limited proportion of selected patients, and 
this has led to the investigation of alternative approaches, 
especially neuroprotection (Broderick 2000, Ferro 2006, 
Fisher 2006, Hacke 2006). Neuroprotective drugs aim to 
salvage the penumbra, limit the infarction size, prolong 
the time window for reperfusion therapy, and/or minimize 
postischemic reperfusion injury, the inflammation and the 
risk of haemorrhage (Gutierrez 2000, Rodriguez-Yanez 
2006, Serena 2006).  Neuroprotective therapies have 
been effective in experimental models of ischemia, but, 
now, there is no definitive evidence of benefit in the 
numerous trials carried out on humans, although some 
subgroups of patients seem to benefit from some of them Journal of Medicine and Life Vol. 3, No.3, July‐September 2010, pp.297‐307  
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(De Keyser 1999, Martinez-Villa 2001, Ovbiagele 2003, 
Labiche 2004, Lizasoain 2006). Cerebrolysin (Cere) is a 
compound with neurotrophic and neuroprotective 
activities, which has shown promise in earlier 
experimental and clinical stroke studies. It is produced by 
enzymatic breakdown of purified brain proteins and 
consists of biologically active low molecular weight 
peptides and free aminoacids (Schwab 1997, Parsons 
2000, Saton 2000, Frey  2002, Schauer 2006). Several 
European small trials have suggested that Cerebrolysin 
improves motor function, cognitive performance and 
global function of acute stroke patients (Gusev 1994, 
Barolin 1996, Haffner 2001, Ladurner 2001, 2005, 
Muresanu 2004, Skvortsova 2004). 
The current study was conducted to assess the 
efficacy of an adjuvant administration of Cerebrolysin in 
Broca’s aphasics following a first acute ischemic stroke of 
the left middle cerebral artery (MCA). 
Patients and methods 
We conducted a randomized clinical trial from 
September 2005 to September 2009, in which 
departments of neurology from 4 cities of Romania 
participated. A total of 2,212 consecutive right handed 
patients with Broca’s aphasia (native Romanian 
speakers), with an acute left middle cerebral artery 
territorial infarction, were entered in this study. Before the 
stroke, all the 2,212 right-handers showed the preference 
to use the right hand in all one-handed tasks and, in 
bimanual tasks, executed the more precise movements 
with the right hand (data obtained from their relatives) 
(Lecours 1988, Viader 2002). 
All the registered patients underwent a careful 
medical history, physical and neurological examination, 
routine blood examinations, urinanalysis, 
electrocardiogram, chest X-rays, and nonenhanced brain 
CT scans, at admission. Particular attention was given at 
admission to language function, which was evaluated by 
means of a Romanian version of the Western Aphasia 
Battery (WAB) (Kertesz 1980, Kory Calomfirescu 1996).  
In addition, the following data were assessed in 
all of the patients, by using common data-sheets: (1) age 
and gender; (2) time from onset to hospital arrival; (3) a 
history of stroke (including Broca’s aphasia); (4) site and 
number of acute lesions on CT and MRI; (5) stroke 
subtype (clinical category); (6) National Institutes of 
Health Stroke Scale (NIHSS) score on admission. 
The clinical categories were defined by using 
clinical and radiographic diagnosis rubrics according to 
the Classification of Cerebrovascular Diseases III, 
developed by the National Institute of Neurological 
Disorders and Stroke (1990). The main subtypes 
included: (1) large artery disease (LAD) was presumed in 
patients with significant stenosis (>50%) of the lumen 
diameter or occlusion of the main trunk of the left internal 
carotid artery (ICA); (2) cardio embolism (CE) mainly 
included atrial fibrillation, left ventricular dyskinetic 
segment, recent myocardial infarction with dyskinetic 
segment, intracardiac thrombus or tumour, 
cardiomyopathy, and other less common sources, (3) 
small artery disease was presumed in patients with 
lacunar infarcts and in patients with hypertension, and/or 
diabetes mellitus in the absence of LAD and CE; (4) 
mixed etiology was presumed in the coexistence of LAD, 
CE and/or small artery diseases; (5) other strokes (Hacke 
2006, Masdeu 2006). 
Conventional Magnetic Resonance Imaging 
(MRI), Duplex Sonography of the carotid and vertebral 
arteries (My LAB 50 ESaote), transcranial Doppler 
(Explorer CVS-DMS systems), Magnetic Resonance 
angiography (MRA), and transthoracic echocardiography 
(TTE) were performed. MRI of the brain was performed 
on General Electric Medical System - Signa Horizon Lx 
1.0 T, software Signa Lx versio 9.0. The standardised 
MRI protocol consisted of axial T2-weighted images with 
fluid attenuated inversion recovery (FLAIR), coronal T2-
weighted images and sagittal T1-weighted images. The 
vascular distributions of the infarcts were determined with 
templates of cerebral vascular territories. The 
measurement of stenosis on MRA was computed directly 
on the maximum intensity projection and collapsed views. 
Results that were >50% were considered to constitute 
significant stenosis. 
From these 2,212 Broca’s aphasics registered, 
we selected eligible patients, who met the following 
criteria:  
-20-75 years of age.  
-Admission within 12 hours from the onset of the 
symptoms.  
-A diagnosis of first acute ischemic stroke in the 
territory of the left MCA (CT and MRI were performed 
within the first 48 hours from the symptoms’ onset). We 
excluded the patients with baseline brain CT scan with 
hypodensity or mass effect involving greater than 50% of 
the left MCA territory. However, loss of gray-white 
differentiation, sulcal effacement, and other early CT 
changes that have high inter-rater variability were not 
exclusion criteria (Masdeu 2006). Selected patients had to 
have on MRI examination at admission a single large (>20 
mm diameter) ischemic lesion in the territory of the left 
MCA.  
-We excluded the patients with large artery 
disease (LAD) and additional clinical small vessel 
abnormalities revealed by FLAIR or T2-weighted MRI 
slices. A control MRI was performed 3 months later for all 
the selected patients who survived, in order to identify an 
eventual new cerebral lesion. All of them remained with a 
single lesion at 90 days.  
-The presence of a large artery disease (LAD) 
stroke (Doppler ultrasonography, and transthoracic 
echocardiography were performed within 48 hours from 
the symptoms’ onset).  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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-A National Institute of Health Score Scale 
(NIHSS) score of 5-22 points on admission. A senior 
neurologist from each department determined the NIHSS 
score, independently of Doppler ultrasonography and 
neuroimaging results. 
  Exclusion  criteria  were the following: acute 
myocardial infarction, preceding dementia, other severe 
concomitant diseases (renal and/or hepatic insufficiency), 
participation in other studies. Concomitant use of 
nootropic drugs (e.g. piracetam), drugs with dilating 
effects on cerebral blood vessels, as well as chronic 
intake of anti-depressants, tranquilizers, sedatives or CNS 
stimulants were prohibited (Haffner, 2001).  
Eligible patients were divided into three groups: 
Cerebrolysin group. The patients received 
standard therapy and adjuvant therapy with Cerebrolysin 
within a therapeutic time window shorter than 72 hours; 
Placebo group. Patients received standard 
therapy and placebo treatment within 72 hours from 
stroke onset. They were matched to the Cerebrolysin 
group patients, with respect to age, gender, NIHSS and 
WAB scores.   
The third group. Patients received only standard 
therapy within 72 hours from stroke onset. Their evolution 
will be reported separately. 
The local ethics committees approved the 
protocol of the study, and a written informed consent was 
obtained for all the selected patients from their relatives. 
Immediately after the selection of the two groups and the 
baseline evaluation, patients were put on study 
medication, once daily i.v. infusions (in a peripheral vein 
over a period of 20 minutes) of active medication or 
placebo for 21 consecutive days. The active medication 
contained 30 ml of Cerebrolysin mixed with 70 ml of 
normal saline. Placebo contained 100 ml of normal saline. 
In addition to the study treatment, both the active and the 
control group patients received standard therapy, 
including acetylsalicylic acid (ASA) (250 mg/day, p.o.) 
which was continued during the follow-up examination on 
day 90 and beyond. 
 
Efficacy assessment 
Seven evaluation visits were scheduled for the 
selected patients of the two groups: at baseline (day 0) 
and at all subsequent study visits, on study days 1, 3, 7, 
14, 21 (the last day of active treatment), and day 90. 
Patients were evaluated by physicians who were 
unblinded to treatment group allocation. 
 
Study objectives 
The aim of the study was to investigate the 
following issues in Broca’s aphasics following the first 
acute ischemic stroke of the left MCA: 
•  Primary end point: the effects of Cerebrolysin 
in comparison with placebo in language 
performance in all subsequent study visits, on 
days 1, 3, 7, 14, 21 and 90. 
•  Secondary end points: 
(a)- to assess clinical outcome at 90 days 
between Cerebrolysin group and placebo group; 
(b)- to compare the mortality rate between the 
two groups at 90 days; 
(c)- to determine the safety of Cerebrolysin 
treatment: emergent adverse events (AEs). 
The following clinical evaluation scales were 
used: 
a) the National Institutes of Health Stroke Scale 
(NIHSS) (at baseline); 
b) the Romanian version of the Western Aphasia 
Battery (WAB), (Kertesz 1980, Kory Calomfirescu 1996), 
which evaluated the language function. WAB included the 
assessment of spontaneous speech (SS), comprehension 
(C), repetition (R) and naming (N). We have calculated 
the scores and have established the aphasia quotient 
(AQ) for all the 7 visits (Table I); 
c) the modified Rankin Scale (mRS) score was 
used to assess the clinical outcome at 90 days between 
the 2 groups;  
d) we compared the mortality rate between the 
two groups at 90 days. 
 
 
 
 
Subscale  Maximum score 
Spontaneous Speech (SS)   
Functional content (SSFC)  10 
Fluency (SSFL)  10 
SS score=SSFC+SSFL  10+10=[20]* 
Comprehension (C)   
Yes/no questions (CYN)  60 
Auditory word recognition (CWD)  60 
Sequential commands (SCO)  80 
C score=(CYN+CWD+SCO)/20  (60+60+80)/20=[10]* 
Repetition (R) score  100/10=[10]* 
Naming   
Object naming (OBNA)  60 
Table I The Aphasia Quotient (AQ) Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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Word fluency (WDFL)  20 
Sentence completion (SECO)  10 
Responsive speech (RESP)  10 
N score=(OBNA+WDFL+SECO+RESP)/10  (60+20+10+10)/10=[10]* 
APHASIA QUOTIENT 
AQscore=(SSscore+Cscore+Rscore+Nscore)x2 
Add above totals in [...] in rows marked by *, then x2 =(20+10+10+10)x2=100 
 
The efficacy of Cerebrolysin was evaluated 
based on the functional and the language function 
assessment of the patients. (Lecours 1988, Viader 2002). 
The evolution of motor functions, cognitive 
performances, and global clinical impressions will be 
reported separately. 
 
Statistical analysis 
The comparison of the two groups (Cerebrolysin 
group and placebo group) with regard to demographic 
and background characteristics was assessed by using 
descriptive statistics and appropriate parametric and non-
parametric statistical tests. Data from Visit 1 (day 0) were 
used for the primary analysis of spontaneous speech 
(SS), comprehension (C), repetition (R), and naming (N) 
subscores, and Aphasia Quotient (AQ) total scores. The 
secondary analysis included the data on days 1, 3, 7, 14, 
21 (the last day of the active treatment), and day 90. The 
mean score at the specific visit and the mean score 
change from baseline visit for all efficacy measures, were 
analysed. Student's t-test or non-parametric Mann-
Whitney U test were used in the comparison of 
continuous variables between the groups, total scores 
and score changes from baseline as appropriate. 
Because the tests for equality of variance proved a 
significant difference, in the selected cases (e.g. A Q at 
visit 2-day 0, or SS at visit 6-day 21) we used modified t-
test with Welch’s correction. Efficacy variables were 
analysed by using two-tailed statistics. We compared the 
mRS scores and mortality between the two groups. We 
used the χ2 test for favourable outcome (mRS score 0-2) 
and mortality. A p value <0.05 was considered statistically 
significant in all tests. 
STATA VERSION 9.2 software was used for all 
calculations. 
Results 
  From 2,212 patients registered, 425 were eligible 
(Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Flow chart showing process of 
patient selection 
Legend: MCA-middle cerebral artery, 
CT-computer tomography, MRI-
magnetic resonance imaging, 
Doppler-Duplex carotid and vertebral 
Sonography, TTE-transthoracic 
echocardiography, LAD-large artery 
disease, NIHSS-National Institute of 
Stroke Scale, WAB-Western Aphasia 
Battery. 
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From the 425 eligible patients, fifty-two patients 
met the criteria of inclusion in the Cerebrolysin group, and 
one hundred and four patients were selected for the 
Placebo group (Figure 1). 
 
Baseline characteristics of the two groups 
 
Table II shows the baseline characteristics of the 
Cerebrolysin group (n=52) and placebo group (n=104). 
 
 
 
 
 
 
 
Patients 
Cerebrolysin group 
(n=52) 
Placebo/group 
 (n=104)  
p 
value  
Gender, F/M  14/38  30/74  0.801 
Age, years (mean+/- SD)  66+/-8  65+/-8  0.462 
The median NIHSS score on admission  14  14  1.000 
Interval time from stroke onset to hospitalization, h (mean +/- SD)  8.2+/-2.4  7.8+/-2.6  0.354 
Interval time from stroke onset to active or placebo treatment, h, (mean+/- 
SD) 
38.3+/-10.2  39.4+/-11.1  0.550 
Initial SS scores (mean+/- SD)  4.09+/-1.89  4.13+/- 1.91  0.901 
Initial C scores (mean+/- SD)  8.52+/-0.51  8.49+/-0.50  0.726 
Initial R scores (mean+/- SD)  3.91+/-0.87  3.87+/-0.86  0.785 
Initial N scores (mean+/- SD)  4.12+/-0.98  4.07+/-0.97  0.762 
Initial AQ scores (mean+/- SD)  41.28+/-6.67  41.12+/-6.59  0.887 
mRS ≤2 ,(%) at baseline  19.2% (n=10)  19.2% (n=20)  1.000 
 
The most common sites of single infarcts in the 
territory of the left MCA of the 156 Broca’s aphasics 
selected were left inferior frontal, left inferior parietal and 
/or left insula (44 patients-84.6% of the Cerebrolysin 
group and 90 patients -86.5% of the placebo group). In 
other cases, there was a deviation from the classic 
clinical-anatomic correlations of Broca’s aphasia: left 
superior temporal: 8 patients in the Cerebrolysin group 
and 14 patients in the placebo group. (Lecours 1988, 
Basso 1995, Kreisler 2000). 
Aphasia and stroke etiology (Table III). 
 
 
 
Group of pts  Cerebral 
infarcts 
Number 
of pts n 
(%) 
P-value  Large artery disease  Number of 
pts n (%) 
P-value 
Ipsilateral or bilateral 
ICA diseases (extra, 
and/or intracranial 
stenosis or occlusions) 
48 
(92.3%) 
 
-Left 
inferior 
frontal 
-left 
inferior 
parietal 
-left 
insula 
 
 
44 
(84.6%) 
ICA diseases+MCA 
diseases 
3 (5.8%) 
 
Cerebrolysin group 
n=52 
-Left 
superior 
temporal 
8 
(15.4%) 
MCA diseases  1 (1.9%) 
 
Ipsilateral or bilateral 
ICA diseases (extra, 
and/or intracranial 
stenosis or occlusions) 
93 (89.4%) 
 
placebo group 
n=104 
 
 
-Left 
inferior 
frontal 
-left 
inferior 
parietal 
-left 
insula 
 
 
 
90 
(86.5%) 
0.745 
 
ICA diseases+MCA 
diseases 
9 (8.7%) 
 
 
0.816 
Table II Characteristics of the two groups (Cerebrolysin group, and placebo group) at baseline 
Legend: F-female, M-male, SD-standard deviation, SS-spontaneous speech, C-comprehension,  
 R-repetition, N-naming, AQ-aphasia quotient, mRS-modified Rankin Scale. 
Aphasia and cerebral infarcts (table III) 
 
Table III  Aphasia, cerebral infarcts and stroke etiology Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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  -Left 
superior 
temporal 
14 
(13.5%) 
MCA diseases  2 (1.9%) 
 Legend: ICA-internal carotid artery, MCA-middle cerebral artery. 
 
Primary end-point: the effects of Cerebrolysin in 
comparison with placebo in language performance in all 
subsequent study visits, on days 1, 3, 7, 14, 21, and 90. 
 
The evolution of Broca’s aphasia 
The mean AQ scores and the mean scores for 3 
subtests of WAB (Spontaneous Speech-SS, Repetition-R, 
and Naming-N) improved over time in both groups, but 
the Cerebrolysin group had a significant improvement 
(p<0.05) over the placebo group (Figure 2,3,4,5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This improvement of language functions was 
evident at all study time points, but the drug-placebo 
difference in favour of Cerebrolysin was most pronounced 
during the first 7 days of treatment (Figure 6,7,8,9). 
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Fig. 2 Time course of AQ score from day 0 to day 90 
in the Cerebrolysin group and in the placebo group 
Legend: AQ score=aphasia quotient score= 
SS score+C score+R score+N score)x2 
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Fig. 3 Time course of SS score from day 0 to day 
90 in the Cerebrolysin group and in the placebo group 
Legend: SS score=spontaneous speech score= 
SSFC (functional content) score+SSFL  (fluency) score 
Evolution of R score
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Fig. 4 Time course of R score from day 0 to day 90
in the Cerebrolysin group and in the placebo group 
Legend: R score=repetition score/10 
+WDFL (word fluency) score+SECO  
(sentence completion) 
score+RESP (responsive speech) score]/10 
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Fig. 5 Time course of N score from day 0 to day 
90 in the Cerebrolysin group and in the placebo group 
Legend: N score=naming score=[OBNA 
 (object naming) score 
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Interestingly, the effect of Cerebrolysin was 
maintained after cessation of the treatment up to the 21-
day assessment, during the overall period of 90 days.  
No significant treatment differences have been 
noticed with the Comprehension subtest of WAB. The 
baseline scores for both groups (8.52 for Cerebrolysin 
and 8.49 for placebo) were very close to the maximum 
score for Comprehension (10.0) (Figure 10, 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: C score=comprehension score=[CYN (yes/no 
questions) scores+CWD (auditory word recognition) 
scores+SCO  (sequential commands)score]/20 
 
At the final evaluation (day 90), the evolution of 
language functions in the Cerebrolysin group was more 
favourable (Figure 12, Figure 13): 
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Fig. 6 Absolute gain of AQ score 
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Fig. 7 Absolute gain of SS score 
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Fig. 8 Absolute gain of R score 
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Fig. 9 Absolute gain of N score 
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Fig. 10 Evolution of C scores 
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Secondary end-points: 
a) Clinical outcome at 90 days in Cerebrolysin 
group and placebo group 
Patients with favourable outcome (mRS ≤2 at 90 
days) were more frequently observed in the Cerebrolysin 
group than in the placebo group (16 patients-38.09% 
were added to the initial 10 patients with mRS≤2 in the 
Cerebrolysin group, versus 24 patients-28.57% who were 
added to the initial 20 patients with mRS≤2 in the placebo 
group P=0.279). 
 b)Mortality at 90 days in Cerebrolysin group and 
placebo group 
 However, no difference between the two groups 
was seen in the mortality rate (3.8% in each group); 
during the overall period of 90 days. Two patients died in 
the Cerebrolysin group, (one patient with pulmonary 
embolism, one patient with pneumonia) and four patients 
in the control group (two patients with pulmonary 
embolism, two patients with pneumonia).  
The investigators considered no relation with the 
investigational drug in all 6 cases of death. 
c) Safety  
Cerebrolysin and Placebo were both well 
tolerated and safe. The overall incidence of AEs was 
similar in both groups (8 patients-15.4% of Cerebrolysin 
group as compared to 11 patients-10.6% of placebo 
group experienced at least one AE; P=0.387).). 
The most common AEs reported in the 
Cerebrolysin group was hypertension; it occurred with a 
similar frequency in the placebo group (2 patients-3.8% 
versus 4 patients-3.8%, respectively P=1.000). Overall, 
there was no significant difference between the two 
groups with regard to the frequency or nature of adverse 
events. Most AEs were mild to moderate in severity, and 
were classified as not related to the investigational drug. 
Discussion 
Several small trials suggested that Cerebrolysin, 
administered as a continuous infusion for 21 days 
improves motor function and global function, compared to 
placebo (Gusev 1994, Barolin 1996, Haffner 2001, 
3.8
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Ladurner 2005). Larger clinical trials would be required to 
establish the value of continued neuroprotection and to 
determine the pharmacokinetics/dynamics of Cerebrolysin 
(Labiche, Grotta, 2004, Muresanu 2007).  
Future neuroprotection clinical trials need a new 
design concerning stroke type, stroke severity, identifying 
the ischemic penumbra, time window for drug 
administration, combination therapy, dosing regimen, 
statistical power, and study outcomes (Ovbiagele 2003, 
Muresanu 2007). Thus, patients with lacunar strokes 
frequently recover spontaneously, therefore, only patients 
with LAD were included in our study. 
The assessment of cognitive improvement in 
stroke trials has received little attention in the past, where 
studies have clearly concentrated on the neurological and 
functional outcome. This has, perhaps, been partly due to 
an underestimation of the importance of the cognitive 
function, especially the language function, as a predictor 
of rehabilitation outcome after stroke (Muresanu 2004, 
Ladurner 2005). In the present study, we tried to further 
explore the clinical effectiveness of Cerebrolysin in acute 
ischemic stroke with regard to language function 
recovery. 
Outcome measures lump together different 
disabilities (e.g: sensorimotor, cognitive) that may 
respond differently to treatment - thus obscuring treatment 
effects. Because of this, we assessed only language 
functions in a single type of aphasia: Broca’s aphasia 
(Jianu 2001). 
Broca’s aphasia represents a primary deficit in 
language output, with a relative preservation of 
comprehension. The speech production of our patients 
was slow, as compared to normal; the prosody was 
greatly reduced, with significant articulatory disturbances 
and word finding difficulties. Repetition and writing were 
impaired. 
Broca’s aphasia is most often present due to a 
vascular lesion, with frontal suprasylvian localisation, 
especially an embolic infarction (LAD), less often 
atherosclerotic thrombus in the territory of the superior 
division of the middle cerebral artery (MCA) (Viader 
2002). For this reason, we selected only patients with left 
MCA infarctions restricted to the upper division of the left 
MCA, and not complete left MCA stem occlusion or 
occlusion of the left ICA (which produces global aphasia). 
Because of the distribution of the superior 
branch of the MCA, Broca’s aphasia was frequently 
associated with a right side facio-brachial paresis and 
disorders of sensation. In consequence, the baseline 
NIHSS scores were relatively homogeneous for Broca’s 
aphasics in the Cerebrolysin group and the placebo 
group.  
Initial Aphasia Quotient scores were relatively 
homogeneous at baseline in the two groups because all 
Broca’s aphasics presented comprehension scores 
between 8 and 10, and repetition, naming, and 
spontaneous speech scores between 2 and 5. 
Consequently, at baseline, there were no 
significant statistical differences between the two groups. 
For all these reasons, we did not use any adjustments at 
the beginning of the study, and the homogeneity for our 
eligible patients was significant in order to match the 
placebo group with the Cerebrolysin group. 
Our study clearly demonstrates that i.v. adjuvant 
treatment with Cerebrolysin results in statistically 
significant and clinically important improvements of 
language function in patients with Broca’s aphasia with a 
first acute ischemic stroke. We have demonstrated a clear 
improvement of Aphasia Quotient score and of 
Spontaneous Speech (SS), Repetition (R), and Naming 
(N) subscores in our patients sample after Cerebrolysin 
treatment during the first 7 days after the stroke onset, 
indicating a fast onset of action of Cerebrolysin, offering 
the possibility for an earlier rehabilitation (Ladurner 2005). 
Our patients were characterised by mild baseline 
impairment of the comprehension subtest of WAB. The 
average score was close to the maximum test score for 
this scale. Evidently, such a situation induces a 
pronounced ceiling effect, which thereby impedes a 
measurable treatment effect for the test substance. 
In comparison with the placebo treatment, a 
significant effect of Cerebrolysin on language function 
recovery was still evident on day 90, after cessation of 
active treatment on day 21. These data indicate a 
possible disease modifying action and stabilising effect of 
Cerebrolysin, which goes beyond a purely symptomatic 
effect. This long-term stabilising effect can be attributed to 
a potent neuroplasticity inducing effect of Cerebrolysin. 
Patients from the Cerebrolysin group had an 
increased significant frequency of good outcomes, than 
the patients of the placebo-group.  
Cerebrolysin and placebo were both well 
tolerated and safe, and no difference in the mortality rate 
was observed between patients with and without 
Cerebrolysin therapy. 
 
Our study had some limitations:  
The therapeutic time window for inclusion in our 
study was of 72 hours after the onset of the ischemic 
stroke. It is generally accepted that early commencement 
of neuroprotective therapy (within the first 6 hours) 
favours more complete recovery of the impaired 
neurological functions (Ferro 2006, Gutierrez 2006, 
Schauer 2006). However, none of our patients has been 
treated within this therapeutic time window.  
MRI was used in our study conventionally; in 
comparison with this technique,  diffusion-weighted 
imaging (DWI) is more sensitive to the presence of small 
new ischemic lesions or reversible ischemic lesions, 
hours after the onset of the stroke, and it is able to 
differentiate recent ischemic lesions from old ones or 
nonspecific white matter high-signal intensities (Masdeu 
2006). DWI was also reported to be superior to Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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conventional MRI in the detection of multiple ischemic 
lesions (Hacke 2006, Masdeu 2006). 
Moreover, physicians who assessed patients’ 
outcome were not blinded to treatment. Therefore, it is 
possible that the efficacy of Cerebrolysin therapy is 
overestimated.  
In conclusion, despite the limitations associated 
with the small number of patients in our study compared 
to other stroke studies, the mild baseline impairment of 
comprehension, the wide time window of active treatment 
and the use of conventional MRI instead of DWI, our 
study suggests a therapeutic effect of Cerebrolysin in 
acute ischemic patients, in particular with regard to 
language function recovery.  
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